Anticoagulants are commonly used in clinical practice for a variety of indications, including treatment of deep vein thrombosis and pulmonary embolism, prevention of acute ischemic stroke in patients with atrial fibrillation, management of clotting disorders, and treatment of patients with heart valve replacement.1  Currently available oral anticoagulants include vitamin K antagonists (warfarin), direct thrombin inhibitors (dabigatran), and factor Xa inhibitors (eg, direct-acting oral anticoagulants [DOACs] such as apixaban, rivaroxaban, betrixaban, and edoxaban).2,3  Parenteral anticoagulation agents include heparin, low-molecular-weight heparin (LMWH) (enoxaparin), pentasaccharide (fondaparinux), and direct thrombin inhibitors (argatroban and bivalirudin).2,3  Anticoagulation use, particularly the use of DOACs, has increased over the years. Troy and Anderson1  analyzed national trends in oral anticoagulant use among US Medicare beneficiaries from 2011 to 2019. The percentage of Medicare Part D beneficiaries using oral anticoagulants increased from 9.2% to 11.5% during this time. The percentage of these...

You do not currently have access to this content.